Pfizer Appoints New COO
The company has appointed Albert Bourla, PhD, as its new COO.
Pfizer announced on Nov. 13, 2017 that it appointed Albert Bourla, PhD, as its new COO, effective Jan. 1, 2018.
Since early 2016, Dr. Bourla has been the group president of Pfizer’s innovative health business, and has held a range of senior global positions. He holds a PhD degree in the biotechnology of reproduction from the Veterinary School of Aristotle University.
“The naming of a chief operating officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment, said Ian Read, Pfizer chairman and CEO.
Source: Pfizer
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
